Researchers at the University of Toronto's Donnelly Center for Cellular and Biomolecular Research have found nearly one million new exons—stretches of DNA that are expressed in mature RNA—in the human genome.
Feb 9, 2024
0
305
Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. Food and Drug ...
Dec 23, 2020
0
5
Researchers from North Carolina State University and the National Institutes of Health (NIH) have developed a method that stops allergic reactions by removing a key receptor from mast cells and basophils. Their work has implications ...
Nov 21, 2016
0
216
Up to 45% of patients with the most common inherited neuromuscular disease could benefit from a new "cocktail" drug being developed at the University of Alberta, according to research published this week in the Proceedings ...
Feb 23, 2022
1
161
A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial. The trial, ...
Sep 8, 2020
0
42
A small-molecule drug is the first to preserve hearing in a mouse model of an inherited form of progressive human deafness, report investigators at the University of Iowa, Iowa City, and the National Institutes of Health's ...
Jun 28, 2018
0
77
One of the most recognizable characteristics of autism is an amazing diversity of associated behavioral symptoms. Clinicians view autism as a broad spectrum of related disorders, and the origin of the disease's heterogeneity ...
Dec 22, 2020
0
22
An RNA editing technique called "exon skipping" has shown preliminary success in treating a rare and severe form of muscular dystrophy that currently has no treatment, based on a new study from Northwestern Medicine and the ...
Oct 12, 2015
0
138
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer ...
Apr 23, 2018
0
44
Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production ...
Aug 8, 2013
0
1
